Skip to content

Effects of patient-controlled intravnous analgsia with dexmedetomidine on patients after abdominal operation: a prospective, multicenter, blinded, randomized controlled trial

Effects of patient-controlled intravnous analgsia with dexmedetomidine on patients after abdominal operation: a prospective, multicenter, blinded, randomized controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-16007889
Enrollment
Unknown
Registered
2016-01-29
Start date
2016-02-18
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative pain

Interventions

test group:patient-controlled intravnous analgsia with dexmedetomidine
contrast group:patient-controlled intravnous analgsia without dexmedetomidine

Sponsors

Affiliated Hospital of Nantong University.
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with full ability to communicate undergoing selective abdominal operation with general anesthesia,including operation on stomach intestines kidneys liver with endoscope or not, ASA status I-II, aged 18~65years old, no restriction on gender, operation time 1-4 hours and awake extubated.

Exclusion criteria

Exclusion criteria: 1. Allergic to dexmedetomidine or any drugs used during this study; 2. Patients on long-term therapy with narcosis analgeticsedative or non-steroid anti-inflammatory drugs; 3. patients with neuromuscular disorders; 4. patients with endocrine system disease; 5. patients with allergic disorders; 6. patients with mental illness; 7. patients with Cardiac conduction disturbances or allorhythmia HR<50bpm, SBP<100mmHg; 8. patients with blood loss more than 600ml or secondary operation; 9. patients enrolled in other clinical test within 3 months; 10. other situations unsuitable for this study.

Design outcomes

Primary

MeasureTime frame
drug consumption;drug recruitment;

Secondary

MeasureTime frame
total bolus;VAS scores;OAA scores;

Countries

China

Contacts

Public ContactYongtao Gao
gyt19700114@sina.com+86 13962988003

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026